Curis (NASDAQ:CRIS) stockholders approved all five proposals presented at the company’s virtual annual meeting, including the election of two directors and a significant increase in the company’s authorized share count.
Jim Dentzer, Curis’ president, chief executive officer and a member of the board of directors, opened the meeting and welcomed stockholders. He said the meeting was being recorded and noted that validated stockholders could submit questions about the proposals through the annual meeting web portal.
Directors Elected to Three-Year Terms
Stockholders elected Martyn D. Greenacre and Kenneth I. Kaitin as Class 3 directors. The company said the nominees received a plurality of the votes cast.
The two directors will serve three-year terms expiring at the 2029 annual meeting, or until their successors are duly elected and qualified. Dentzer said other Curis directors participating telephonically included Greenacre, Dr. Anne Borgman, Dr. John Hohneker, Dr. Kaitin and Dr. Marc Rubin.
Share Authorization Proposal Approved
Stockholders also approved an amendment to Curis’ restated certificate of incorporation to increase the number of authorized shares of capital stock from 288,757,150 to 572,514,300.
As part of that amendment, the number of authorized shares of common stock will increase from 283,757,150 to 567,514,300. The board had recommended that stockholders approve the authorized shares proposal, and McClelland reported that holders of a majority of votes cast supported it.
Other Proposals Passed
In addition to the director elections and share authorization amendment, stockholders approved the remaining proposals presented at the meeting:
- An advisory, non-binding vote approving the company’s executive compensation.
- Ratification of PricewaterhouseCoopers LLP as Curis’ independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
- Approval of an adjournment proposal that would allow the meeting to be adjourned to a later date or dates, if necessary or appropriate, to solicit additional proxies in connection with the authorized shares proposal.
The company said the final voting results will be included in a Form 8-K to be filed within four business days after the meeting.
The formal portion of the meeting included a standard forward-looking statements disclaimer. The company said actual results may differ materially from expectations due to factors discussed in its filings with the Securities and Exchange Commission, including its Form 10-K and Form 10-Q reports.
After the preliminary results were announced, the company adjourned the formal meeting. Dentzer thanked stockholders for attending and for their ongoing support of Curis.
About Curis (NASDAQ:CRIS)
Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.
Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.
